Cargando…

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

This single‐center, open‐label, non‐randomized, two‐part, phase I study was conducted (1) to evaluate the absolute oral bioavailability of rilzabrutinib 400 mg tablet following an i.v. microtracer dose of ~100 μg [14C]‐rilzabrutinib (~1 μCi) and single oral dose of 400 mg rilzabrutinib tablet (part...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ucpinar, Sibel, Smith, Patrick F., Long, Li, Li, Fujun, Yan, Hui, Wadhwa, Jyoti, Chu, Katherine A., Shu, Jin, Nunn, Philip, Li, Mengyao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339699/ https://www.ncbi.nlm.nih.gov/pubmed/37060187 http://dx.doi.org/10.1111/cts.13524

Ejemplares similares

A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects
por: Ucpinar, Sibel, et al.
Publicado: (2022)

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study
por: Murrell, D.F., et al.
Publicado: (2021)

P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
por: Kuter, David, et al.
Publicado: (2023)

Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia
por: Hu, Jun-Hao, et al.
Publicado: (2019)

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
por: Gu, Danling, et al.
Publicado: (2021)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023)

Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations
por: Voice, Angus T., et al.
Publicado: (2021)

Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2014)

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
por: Scheible, Holger, et al.
Publicado: (2021)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Pharmacokinetics, bioavailability, and excretion of ponazuril in piglets
por: Wang, Wenxiang, et al.
Publicado: (2022)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2021)

Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability
por: K. Pinjari, M. Jakir S., et al.
Publicado: (2017)

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
por: Qiu, Simei, et al.
Publicado: (2021)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
por: Martin, Elodie, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
por: Zhang, Heather, et al.
Publicado: (2021)

Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]‑BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2022)

Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
por: Litzenburger, Tobias, et al.
Publicado: (2020)

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
por: Catlett, Ian M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m1u2ab6r6aht5dt0lukqr4pipk